Soft Endpoint Sought for Pediatric PAH Trial

(MedPage Today) — An FDA advisory panel will revisit an increasingly familiar battleground this week, as it considers whether a sponsor can substitute a surrogate endpoint for a clinical outcome in a pediatric pulmonary arterial hypertension (PAH) trial.


Read more

Related posts

Leave a Reply